Nancy Verhoff, MD
Family Medicine · Willard, OHNPI 1275535882
Payments from drug & device makers
Across 156 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$722
- AstraZeneca$214
- Pfizer$176
- Merck$143
- Astellas Pharma US Inc$117
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$74
- plus $704 from 19 others
What the payments were for
- Food & beverage$2,145100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $722 |
| AstraZeneca | 15 | $214 |
| Pfizer | 16 | $176 |
| Merck | 11 | $143 |
| Astellas Pharma US Inc | 8 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $74 |
| GSK | 5 | $72 |
| Amarin Pharma, Inc. | 4 | $70 |
| Bayer | 5 | $68 |
| Novo Nordisk | 5 | $62 |
| Exact Sciences | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Dexcom, Inc. | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Lilly USA, LLC | 3 | $35 |
| Johnson & Johnson | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Amgen | 2 | $23 |
| Boehringer Ingelheim | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,150 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $69,203 |
| JardianceEmpagliflozin | 53 | $44,802 |
| OzempicSemaglutide | 46 | $44,256 |
| JanuviaSitagliptin Phosphate | 37 | $39,440 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $22,678 |
| FarxigaDapagliflozin Propanediol | 30 | $19,507 |
| MounjaroTirzepatide | 12 | $12,620 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $11,123 |
| TrulicityDulaglutide | 11 | $10,814 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $10,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,999 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $5,528 |
| Potassium Chloride | 175 | $4,102 |
| Atorvastatin Calcium | 555 | $4,038 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $3,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $176 | $69,20399 claims |
| Boehringer IngelheimJardiance | $23 | $44,80253 claims |
| Novo NordiskOzempic | $62 | $44,25646 claims |
| MerckJanuvia | $143 | $39,44037 claims |
| Lilly USA, LLCMounjaro, Trulicity | $35 | $23,43423 claims |
| AstraZenecaFarxiga | $214 | $19,50730 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $72 | $18,43535 claims |
| Sanofi-aventis U.S. LLCLantus | $21 | $3,75212 claims |
| AbbVieSynthroid | $722 | $2,39089 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Willard
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.